SCHEMBL4673383

SCHEMBL4673383

Nc1ccc(Cc2cc(C(=O)C=C(O)C(=O)O)co2)cc1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.37
ITGB1 P05556 2/20 0.34
ITGA5 P08648 2/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33
MEN1 O00255 1/20 0.30
PSMD14 O00487 1/20 0.30
MAPT P10636 1/20 0.30
CRHBP P24387 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
CRHR2 Q13324 1/20 0.30
CYP1B1 Q16678 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673378 1.00 IDH1 (0.37) IDH1ITGB1ITGA5ALDH1A1CYP3A4
SCHEMBL4674730 0.88 IDH1 (0.49) IDH1
SCHEMBL4674726 0.88 IDH1 (0.49) IDH1
SCHEMBL4671175 0.87 KDM4E (0.38) IDH1ALDH1A1MAPT
SCHEMBL4675448 0.87 SRD5A2 (0.39) IDH1ALDH1A1TDP1MEN1MAPT
SCHEMBL4671179 0.87 KDM4E (0.38) IDH1ALDH1A1MAPT
SCHEMBL4675452 0.87 SRD5A2 (0.39) IDH1ALDH1A1TDP1MEN1MAPT
SCHEMBL4676200 0.86 KMT2A (0.45) IDH1ALDH1A1CYP3A4TSHRMAPT
SCHEMBL4676204 0.86 KMT2A (0.45) IDH1ALDH1A1CYP3A4TSHRMAPT
SCHEMBL4671554 0.84 IDH1 (0.37) IDH1ALDH1A1TSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 IDH1 72/4885ITGB1 2186/4885ITGA5 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.